Oxford BioDynamics PLC Notice of Interim Results Webinar (2334P)

TIDMOBD

RNS Number : 2334P

Oxford BioDynamics PLC

17 June 2022

17 June 2022

Oxford BioDynamics Plc

( " OBD " or the " Company " and, together with its subsidiaries, the " Group " )

Interim Results Webinar

Oxford Biodynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch(R) 3D genomics platform , is pleased to announce that the Company's management team will conduct a live presentation via the Yellowstone Advisory webinar platform to investors following their interim results for the half-year ended 31 March 2022, which will be released at 7am on 28 June 2022.

The online presentation is open to both existing and potential shareholders. Questions can be submitted both before the presentation by emailing [e-mail] and during the presentation and will be addressed at the end.

The event will take place at 12pm BST on Tuesday 28 June 2022.

To register for the presentation, please visit:

https://us02web.zoom.us/webinar/register/1016520892457/WN_HwJq5cd6QTCcL9Tl0FwLrQ

-Ends-

For further details please contact:

 
 Oxford BioDynamics Plc                                   Tel: [phone] 
  Jon Burrows, CEO                                                  518910 
  Paul Stockdale, CFO 
 Shore Capital - Nominated Adviser and                      Tel: +44 (0)20 
  Broker                                                         7408 4090 
  Advisory: Stephane Auton / John More 
  Broking: Fiona Conroy 
 Instinctif Partners                                        Tel: +44 (0)20 
  Melanie Toyne-Sewell / Jonjo Cordey                            7457 2020 
                                          [e-mail] 
 Yellowstone Advisory                         [e-mail] 
 

Notes for Editors

About Oxford BioDynamics Plc

Oxford BioDynamics Plc (AIM: OBD) is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch(R) CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch (R) CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch(R) Explorer Array Kit .

The Company has developed a proprietary 3D genomic biomarker platform, EpiSwitch(R), which can build molecular diagnostic classifiers for prediction of response to therapy, patient prognosis, disease diagnosis and subtyping, and residual disease monitoring in a wide range of indications.

Oxford BioDynamics has participated in more than 40 partnerships with big pharma and leading institutions including Pfizer, EMD Serono, Genentech, Roche, Biogen, Mayo Clinic, Massachusetts General Hospital and Mitsubishi Tanabe Pharma.

The Company has created a valuable technology portfolio, including biomarker arrays, molecular diagnostic tests, bioinformatic tools for 3D genomics and an expertly curated 3D genome knowledgebase comprising hundreds of millions of data points from over 10,000 samples in more than 30 human diseases.

OBD is headquartered in Oxford, UK and is listed on AIM of the London Stock Exchange. It also has a commercial office in Gaithersburg, MD, USA and a reference laboratory in Penang, Malaysia.

For more information, please visit the Company's website, www.oxfordbiodynamics.com , or follow on Twitter or LinkedIn .

About EpiSwitch(R)

The 3D configuration of the genome plays a crucial role in gene regulation. By mapping this architecture and identifying abnormal configurations, EpiSwitch(R) can be used to diagnose patients or determine how individuals might respond to a disease or treatment.

Built on over 10 years of research, EpiSwitch(R) is Oxford Biodynamics' award-winning, proprietary platform that enables screening, evaluation, validation and monitoring of 3D genomic biomarkers. The technology is fully developed, based on testing of over 10,000 samples in 30 disease areas, and reduced to practice.

In addition to stratifying patients with respect to anticipated clinical outcome, EpiSwitch(R) data offer insights into systems biology and the physiological manifestation of disease that are beyond the scope of other molecular modalities. The technology has performed well in academic medical research settings and has been validated through its integration in biomarker discovery and clinical development with big pharma.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

MSCUBUURUNUNARR

(END) Dow Jones Newswires

June 17, 2022 02:00 ET (06:00 GMT)